Maculopathy, Age-Related Clinical Trial
Official title:
Pilot Study of the Combination of Anecortave Acetate 15mg Delivered by Posterior Juxtascleral Injection and Triamcinolone Acetonide 4mg Delivered by Intravitreal Injection for the Treatment of Exudative Age-Related Macular Degeneration (AMD)
NCT number | NCT00211419 |
Other study ID # | Double Injection |
Secondary ID | |
Status | Completed |
Phase | Phase 1 |
First received | September 13, 2005 |
Last updated | October 23, 2012 |
The purpose of this study is to evaluate the safety of combining juxtasclerally administered anecortave acetate 15 mg with triamcinolone acetate 4 mg administered intravitreally following photodynamic therapy with verteporfin for the treatment of exudative age-related macular degeneration (AMD).
Status | Completed |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 50 Years and older |
Eligibility |
Inclusion Criteria: 1. A male or female with evidence of exudative age-related macular degeneration with clinical/angiographic/optical coherence tomography (OCT) findings of subfoveal choroidal neovascularization (CNV) which has not responded to current therapy 2. Baseline best-corrected visual acuity (BCVA) 20/40 to 20/640 3. Patient must be willing and able to comply with the protocol and provide informed consent. Exclusion Criteria: 1. Patients on intravenous, subcutaneous, or anticoagulant therapy (with the exception of aspirin and antiplatelet therapy) and cannot take a 5 day holiday from therapy prior to the injection procedure. Note: Patients on oral anticoagulant therapy may be considered to participate if the physician responsible for monitoring the anticoagulant therapy agrees that the patient may take a 5 day holiday from therapy prior to each anecortave injection. The attending doctor must notify the principal investigator and this notification will be made part of the source documentation. Anticoagulant therapy may resume either the evening of or the morning after the injection procedure. 2. Patient with known glaucoma or steroid induced ocular hypertension 3. Intraocular pressures of 21 mmHg or greater at time of entry into the study 4. Patient with significantly compromised visual acuity in the study eye due to concomitant ocular conditions 5. Patients who have undergone intraocular surgery within last 2 months or capsulotomy within last month in study eye 6. Patient participating in any other investigational drug study 7. Inability to obtain photographs to document CNV (including difficulty with venous access) 8. Concomitant oral steroids or topical ophthalmic steroid use 9. Sub-Tenon's injection of steroids within the past 6 months 10. Patient with significant liver disease or uremia 11. Patient with known adverse reaction to indocyanine green, iodine, verteporfin, or triamcinolone 12. Patient is pregnant or nursing 13. Age less than 50 years old |
Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Manhattan Eye, Ear & Throat Hospital | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Manhattan Eye, Ear & Throat Hospital | Alcon Research |
United States,
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00058994 -
An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD
|
Phase 3 | |
Completed |
NCT00417846 -
Age-related Macular Degeneration: Detection of Onset of New Choroidal Neovascularization (AMD DOC Study)
|
N/A | |
Completed |
NCT00051129 -
Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)
|
Phase 3 | |
Completed |
NCT01024998 -
Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)
|
Phase 1 | |
Recruiting |
NCT00331253 -
Treatment of Patients With Neovascular AMD Using Indocyanine Green-Mediated Photothrombosis (i-MP).
|
Phase 2 |